A Randomized, Double-Blind, Placebo-Controlled, Study Evaluating the E
Research payments
$5,937,931
Through program year 2023, $5,937,931 in research payments was reported against A Randomized, Double-Blind, Placebo-Controlled, Study Evaluating the E, across 351 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $19,148 | 3 |
| 2022 | Research | $431,435 | 45 |
| 2021 | Research | $1,160,865 | 190 |
| 2020 | Research | $4,326,484 | 113 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Lee Schwab Silver Spring, MD Named on 28 payments
- Les Szekely Doylestown, PA Named on 28 payments
- Charlene McEvoy Hudson, WI Named on 27 payments
- Timothy Hatlen Torrance, CA Named on 17 payments
- Zainab Shahid Charlotte, NC Named on 15 payments
- Allan Seibert Mobile, AL Named on 13 payments
- Timothy Albertson Sacramento, CA Named on 13 payments
- Peruvemba Sriram Gainesville, FL Named on 12 payments
- Dorothy Garner Roanoke, VA Named on 11 payments
- Bryant Nguyen La Mesa, CA Named on 11 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.